Abstract #4862

A multicenter in vivo study to evaluate gadoxetate DCE-MRI as a preclinical biomarker of liver function

Paul Hockings^1,2, Anastassia Karageorgis³, Stephen Lenhard⁴, Brittany Yerby⁵, Mikael Forsgren^6,7, Serguei Liachenko⁸, Edvin Johansson³, Richard Peterson⁹, Xi Yang⁸, Dominic Williams¹⁰, Sharon Ungersma⁵, Ryan Morgan⁵, Kim Brouwer¹¹, and Beat Jucker⁴

¹Antaros Medical, Molndal, Sweden, ²MedTech West, Chalmers University of Technology, Gothenburg, Sweden, ³AstraZeneca, Molndal, Sweden, ⁴GlaxoSmithKline, King of Prussia, PA, United States, ⁵Amgen Inc., Thousand Oaks, CA, United States, ⁶Linköping University, Linköping, Sweden, ⁷Wolfram MathCore, Linköping, Sweden, ⁸National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, United States, ⁹AbbVie, North Chicago, IL, United States, ¹⁰AstraZeneca, Cambridge, United Kingdom, ¹¹University of North Carolina, Chapel Hill, NC, United States

Gadoxetate dynamic contrast-enhanced MRI (DCE-MRI) seems promising for non-invasive quantification of liver function. Here we tested the reproducibility of gadoxetate DCE-MRI at four MRI sites using an acute clinical dose of the antibiotic rifampicin. We found significant differences between sites in maximum relative enhancement (RE) in vehicle treated rats. However, highly significant differences in maximum RE between vehicle and rifampicin treated rats was detected at all sites. To our knowledge this is the first multicenter preclinical reproducibility study of an imaging biomarker.

This abstract and the presentation materials are available to members only; a login is required.

Join Here